MAIA

#4038
MAIA Biotechnology, Inc. Common Stock
1.3 2 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.31
1.32
Jahresspanne
1.16
2.46
Tagesänderung
-0.75%
Monatliche Änderung
-4.35%
6 month change
-14.84%
Jahresänderung
-36.54%
Vorheriger Schlusskurs
1.3 3
Open
1.3 1
Tief
1.3 1
Hoch
1.3 2
Volumen
20
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Quarterly report, Q2 FY2026
MAIA Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MAIA Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K

MAIA Biotechnology, Inc. current report, Q1 FY2025

Full document

MAIA Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

MAIA Biotechnology, Inc. (MAIA), a Delaware corporation, filed this Current Report on Form 8-K on February 5, 2025, covering events occurring on February 4, 2025. The Company is an emerging growth company with its principal executive offices in Chicago, Illinois. The filing primarily serves to disclose material non-public information regarding clinical trial updates and to provide access to investor presentation materials.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As a Form 8-K focused on regulatory disclosure and corporate events, the document does not report quantitative financial performance metrics.

Material Changes and Events

  • Regulation FD Disclosure (Item 7.01): On February 4, 2025, the Company issued a press release announcing efficacy updates for its Phase 2 THIO-101 trial in advanced non-small cell lung cancer. This press release is attached as Exhibit 99.1.
  • Other Events (Item 8.01): On February 5, 2025, the Company posted a business presentation to its website, filed as Exhibit 99.2, which is incorporated by reference into this report.

Guidance, Outlook, and Risks

The filing explicitly states that the attached presentation contains forward-looking statements. Management disclaims any obligation to update these statements to reflect future events or circumstances. The information provided in the press release and presentation is deemed "furnished" rather than "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.

Investor Verification Checklist

  • Review the full text of the press release (Exhibit 99.1) for specific efficacy data points regarding the THIO-101 Phase 2 trial.
  • Examine the investor presentation (Exhibit 99.2) for updated business strategy and clinical timelines, noting the disclaimer regarding forward-looking statements.
  • Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
  • Confirm that no financial metrics were disclosed in this specific filing and refer to the most recent 10-K or 10-Q for financial health indicators.

Nachrichten